NewsBenzingaCorcept Therapeutics reafirma su guía de ventas para el ejercicio fiscal 2026 de entre $1.100B y $1.200B frente a una estimación de $1.146B Corcept Therapeutics reafirma su guía de ventas para el ejercicio fiscal 2026 de entre $1.100B y $1.200B frente a una estimación de $1.146B Benzinga 2026.11.03 21:12 (GMT+0) Open on Benzinga Other news Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Binance to Remove 5 Spot Trading Pairs Including GAS/TRY and HBAR/BNB on November 20 Micron Technology (MU) Stock Is Trending After Hours: Here's Why
Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead